03/30/1998 - "Combination of CGP 59326A with cytotoxic agents resulted in tumor regression and cures. "
03/30/1998 - "In contrast to previously described inhibitors, CGP 59326A had potent and selective in vivo anti-tumor activity at well-tolerated doses against EGF-R-expressing tumors (e.g., ED50 of 0.78 to 1.5 mg/kg for inhibition of A431 tumor growth). "
03/30/1998 - "CGP 59326A inhibited growth of human tumor xenografts expressing the EGF-R but showed little activity against EGF-R-negative xenografts. "
|1.||Epidermal Growth Factor (EGF)
|1.||Heterologous Transplantation (Xenotransplantation)